• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗肿瘤治疗的心脏毒性和诱导多能干细胞衍生心肌细胞的应用。

Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

机构信息

Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

出版信息

Cells. 2021 Oct 21;10(11):2823. doi: 10.3390/cells10112823.

DOI:10.3390/cells10112823
PMID:34831045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8616116/
Abstract

The therapeutic landscape for the treatment of cancer has evolved significantly in recent decades, aided by the development of effective oncology drugs. However, many cancer drugs are often poorly tolerated by the body and in particular the cardiovascular system, causing adverse and sometimes fatal side effects that negate the chemotherapeutic benefits. The prevalence and severity of chemotherapy-induced cardiotoxicity warrants a deeper investigation of the mechanisms and implicating factors in this phenomenon, and a consolidation of scientific efforts to develop mitigating strategies. Aiding these efforts is the emergence of induced pluripotent stem cells (iPSCs) in recent years, which has allowed for the generation of iPSC-derived cardiomyocytes (iPSC-CMs): a human-based, patient-derived, and genetically variable platform that can be applied to the study of chemotherapy-induced cardiotoxicity and beyond. After surveying chemotherapy-induced cardiotoxicity and the associated chemotherapeutic agents, we discuss the use of iPSC-CMs in cardiotoxicity modeling, drug screening, and other potential applications. Improvements to the iPSC-CM platform, such as the development of more adult-like cardiomyocytes and ongoing advances in biotechnology, will only enhance the utility of iPSC-CMs in both basic science and clinical applications.

摘要

近年来,随着有效的肿瘤药物的发展,癌症治疗的治疗景观发生了重大变化。然而,许多癌症药物通常在体内,特别是心血管系统中耐受性差,导致不良且有时致命的副作用,从而抵消了化疗的益处。化疗引起的心脏毒性的流行率和严重程度需要更深入地研究这种现象的机制和牵连因素,并整合科学努力来开发缓解策略。近年来诱导多能干细胞(iPSCs)的出现为此提供了帮助,它允许生成 iPSC 衍生的心肌细胞(iPSC-CMs):这是一种基于人类的、源自患者的、遗传可变的平台,可用于研究化疗引起的心脏毒性及其它方面。在调查了化疗引起的心脏毒性和相关的化疗药物后,我们讨论了 iPSC-CMs 在心脏毒性建模、药物筛选和其他潜在应用中的使用。iPSC-CM 平台的改进,例如开发更像成人的心肌细胞和生物技术的持续进步,将只会增强 iPSC-CMs 在基础科学和临床应用中的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/7ec4a8fc50ba/cells-10-02823-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/241cd3acd922/cells-10-02823-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/b925eb4ed2a6/cells-10-02823-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/7ec4a8fc50ba/cells-10-02823-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/241cd3acd922/cells-10-02823-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/b925eb4ed2a6/cells-10-02823-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4512/8616116/7ec4a8fc50ba/cells-10-02823-g003.jpg

相似文献

1
Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.抗肿瘤治疗的心脏毒性和诱导多能干细胞衍生心肌细胞的应用。
Cells. 2021 Oct 21;10(11):2823. doi: 10.3390/cells10112823.
2
Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.人诱导多能干细胞-心脏内皮肿瘤芯片用于评估抗癌疗效和心脏毒性。
Tissue Eng Part C Methods. 2020 Jan;26(1):44-55. doi: 10.1089/ten.TEC.2019.0248. Epub 2020 Jan 3.
3
Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy.基于人诱导多能干细胞的心肌细胞亚型分化用于药物发现和细胞治疗。
Handb Exp Pharmacol. 2023;281:209-233. doi: 10.1007/164_2023_663.
4
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.心脏肿瘤学中的个性化医学:诱导多能干细胞的作用。
Cardiovasc Res. 2019 Apr 15;115(5):949-959. doi: 10.1093/cvr/cvz024.
5
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs-a proof-of-concept study with doxorubicin.使用供体特异性 iPSC-CM 预测肿瘤药物诱导的心脏毒性-多柔比星的概念验证研究。
Toxicol Sci. 2024 Jun 26;200(1):79-94. doi: 10.1093/toxsci/kfae041.
6
Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.基于细胞的二维形态评估系统,使用人诱导多能干细胞衍生的心肌细胞预测癌症药物诱导的心脏毒性。
Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
7
Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.临床前药物研究:利用患者来源的诱导多能干细胞鉴定药物致心肌毒性的风险。
Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1019-1031. doi: 10.1161/ATVBAHA.120.314695. Epub 2021 Jan 21.
8
Human-induced pluripotent stem cells as models for rare cardiovascular diseases: from evidence-based medicine to precision medicine.人类诱导多能干细胞作为罕见心血管疾病模型:从循证医学到精准医学。
Pflugers Arch. 2021 Jul;473(7):1151-1165. doi: 10.1007/s00424-020-02486-y. Epub 2020 Nov 18.
9
[Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes].利用诱导多能干细胞衍生心肌细胞预测抗癌药物的心脏毒性
Yakugaku Zasshi. 2024;144(3):265-271. doi: 10.1248/yakushi.23-00164-3.
10
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?验证化疗诱导心脏毒性的药物基因组学:缺失了什么?
Pharmacol Ther. 2016 Dec;168:113-125. doi: 10.1016/j.pharmthera.2016.09.009. Epub 2016 Sep 5.

引用本文的文献

1
Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management.铂类化疗中的心脏毒性:机制、表现及管理
Cancer Pathog Ther. 2024 Apr 25;3(2):101-108. doi: 10.1016/j.cpt.2024.04.004. eCollection 2025 Mar.
2
Effect of electrochemical topology on detection sensitivity in MEA assay for drug-induced cardiotoxicity screening.电化学拓扑结构对用于药物诱导心脏毒性筛查的微电极阵列检测灵敏度的影响。
Biosens Bioelectron. 2025 Mar 15;272:117082. doi: 10.1016/j.bios.2024.117082. Epub 2024 Dec 25.
3
Exploring Anthracycline-Induced Cardiotoxicity from the Perspective of Protein Quality Control.

本文引用的文献

1
Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.深度学习技术利用诱导多能干细胞衍生的心肌细胞检测高通量筛选中的心脏毒性。
Elife. 2021 Aug 2;10:e68714. doi: 10.7554/eLife.68714.
2
Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.癌症治疗相关心血管毒性的临床前模型:美国心脏协会的科学声明。
Circ Res. 2021 Jun 25;129(1):e21-e34. doi: 10.1161/RES.0000000000000473. Epub 2021 May 3.
3
Cancer statistics for the year 2020: An overview.
从蛋白质质量控制角度探索蒽环类药物诱导的心脏毒性
Rev Cardiovasc Med. 2024 Jun 13;25(6):213. doi: 10.31083/j.rcm2506213. eCollection 2024 Jun.
4
Understanding the Molecular Basis of iPSC Reprogrammed Cells to Fulfil Their Expectations in Future Clinical Applications.理解 iPSC 重编程细胞的分子基础,以满足未来临床应用的期望。
Cells. 2022 Aug 31;11(17):2714. doi: 10.3390/cells11172714.
2020年癌症统计数据概述。
Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.
4
Building Multi-Dimensional Induced Pluripotent Stem Cells-Based Model Platforms to Assess Cardiotoxicity in Cancer Therapies.构建基于多维度诱导多能干细胞的模型平台以评估癌症治疗中的心脏毒性。
Front Pharmacol. 2021 Feb 18;12:607364. doi: 10.3389/fphar.2021.607364. eCollection 2021.
5
Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells.马法兰通过诱导多能干细胞来源的心肌细胞中的氧化应激诱导心脏毒性。
Stem Cell Res Ther. 2020 Nov 5;11(1):470. doi: 10.1186/s13287-020-01984-1.
6
The EBiSC iPSC bank for disease studies.用于疾病研究的欧洲生物样本库诱导多能干细胞库。
Stem Cell Res. 2020 Dec;49:102034. doi: 10.1016/j.scr.2020.102034. Epub 2020 Oct 9.
7
iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine.iPSC 衍生肝类器官:从药物筛选到疾病建模,再到再生医学的旅程。
Int J Mol Sci. 2020 Aug 27;21(17):6215. doi: 10.3390/ijms21176215.
8
Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection.人诱导多能干细胞衍生的心肌细胞易受新冠病毒感染。
Cell Rep Med. 2020 Jul 21;1(4):100052. doi: 10.1016/j.xcrm.2020.100052. Epub 2020 Jun 29.
9
Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.RARG 变异增加了患者特异性诱导多能干细胞衍生心肌细胞对阿霉素诱导的心脏毒性的易感性。
Sci Rep. 2020 Jun 25;10(1):10363. doi: 10.1038/s41598-020-65979-x.
10
Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity.药物性心脏毒性中心肌细胞死亡的分子机制
Front Cell Dev Biol. 2020 Jun 3;8:434. doi: 10.3389/fcell.2020.00434. eCollection 2020.